Download PDF
Exp Clin Endocrinol Diabetes 1989; 93(2/03): 143-146
DOI: 10.1055/s-0029-1210847
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Ciamexone Suppressed Anti-Islet ADCC of Mononuclear Cells and Serum from Type 1 (Insulin-dependent) Diabetic Patients

E. Köhler1 , S. Knospe1 , H. J. Hahn1 , K. G. Roemer2 , T. Diamantstein3
  • 1Central Institute of Diabetes “Gerhardt Katsch” (Director: OMR Prof. Dr. sc. med. H. Bibergeil) Karlsburg/GDR
  • 2Boehringer Mannheim GmbH, Product Development Division Mannheim/FRG
  • 3Institute for Immunology (Director: Prof. Dr. T. Diamantstein) Klinikum Steglitz of the Free University of Berlin
Further Information

Publication History

1988

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

ADCC (Antibody-dependent cellular cytotoxicity) against xenogenic islets has frequently been found in newly diagnosed Type 1 (insulin-dependent) diabetics suggesting that when combined with autologous serum in vitro, the destruction of islet cells caused by mononuclear cells (MNC) reflects islet destruction in vivo. In this study the ability of Ciamexone to suppress the anti-islet ADCC in vitro was investigated. We selected both ADCC positive and ADCC negative subjects from a group of Type 1 diabetics. The targets, islets from neonatal rats, were incubated for one hour with the probands serum. The ADCC was then measured by the 51Cr-release of the serum-treated islets after a 6h-incubation with MNC of the same donor. Results both with and without co-incubation of Ciamexone were compared. Ciamexone does not influence the spontaneous 51Cr-release from neonatal rat islets treated with the probands serum but significantly suppresses the anti-islet ADCC.

The fact that Ciamexone suppresses anti-islet ADCC may explain its possible effectiveness in Type 1 diabetes.

Key Words

Immuno therapy - Ciamexone - Anti-islet-ADCC - Type I-Diabetes mellitus